A new article summarizes treatment options for women with recurrent ovarian cancer. The article includes information about when to treat a recurrence, what agents are available and the goals of therapy.
Read the full article here
Related Topics
Ovarian Cancer Research Alliance Honors Researchers with 2025 Rosalind Franklin and Schreiber Prizes
Recognizing Advances in Ovarian Cancer Research and Immunotherapy Ovarian Cancer Research Alliance (OCRA) announced today the winners of two prizes recognizing exceptional accomplishments in ovarian cancer research. David Huntsman, MD, FRCPC, FCCMG, was awarded the 2025 Rosalind Franklin Prize for Excellence in Ovarian Cancer Research for his findings that have profoundly impacted the treatment of … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in February 2026 to reflect NCCN’s release of the 2026 Guidelines for Cervical Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer, and the 2025 Patient Guidelines for Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
Global Ovarian Cancer Research Consortium Awards Inaugural AI Accelerator Grant with Microsoft’s AI for Good Lab
$1 million global research award, plus an additional $1 million in compute support, advances AI-driven efforts to personalize ovarian cancer care The Global Ovarian Cancer Research Consortium today awarded its inaugural AI Accelerator Grant to an international team of researchers to examine whether artificial intelligence (AI) can improve how survival and treatment response are predicted … Continued